Indivior Pharmaceuticals Inc
High uncertainty:The valuation methods show significant disagreement (>100% spread). Treat the range as a rough guide rather than a precise estimate.
Bear Case (25th pct.)
-82.9% vs price
Base Case (Median)
-37.8% vs price
Bull Case (75th pct.)
58.9% vs price
◇ = Current price | |Bear |Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $-15.09 | -138.6% | High (40%) |
| PE Comparable | $62.09 | 58.9% | Medium (25%) |
| Growth Trajectory DCF | $152.06 | 289.1% | Medium (20%) |
| EV/EBITDA | $24.32 | -37.8% | Medium (20%) |
| Earnings Power Value | $6.68 | -82.9% | Medium (50%) |
Based on 5 out of 8 methods, INDV appears fairly valued at the current price of $39.08. The base case fair value of $24.32 implies 37.8% downside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.